Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 78 results for psoriasis

  1. Assessment of disease severity and impact:- In children, young people and adults with psoriasis, can tools be developed and/or existing ones further refined and validated to: - assess disease severity and impact in both non-specialist and specialist healthcare settings, to facilitate assessment, appropriate referral, treatment planning and measurement of outcomes - measure burden and cumulative effect of disease activity, severity and impact for people with both psoriasis and psoriatic arthritis?

    disease severity and impact:- In children, young people and adults with psoriasis, can tools be developed and/or existing ones further...

    Research recommendation
    Published
    9 June 2015

  2. Rapid escalation to systemic treatments:- In people with psoriasis, does early intervention with systemic treatments improve the long-term prognosis of psoriasis severity, comorbidities (including psoriatic arthritis), or treatment -related adverse effects, and are there any clinical (for example demographic or phenotypic) or laboratory (for example genetic or immune) biomarkers that can be used to identify those most likely to benefit from this treatment approach?

    treatments:- In people with psoriasis, does early intervention with systemic treatments improve the long-term prognosis of...

    Research recommendation
    Published
    9 June 2015

  3. Zasocitinib for treating moderate to severe plaque psoriasis [ID6700]

    Awaiting development Reference number: GID-TA11926 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Trials that evaluate utility values (using generic preference-based measures) in children and young people with severe psoriasis are needed to better inform future cost–utility analyses.

    generic preference-based measures) in children and young people with severe psoriasis are needed to better inform future cost–utility...

    Research recommendation
    Published
    15 October 2018

  5. Self-management:- Do structured psoriasis-focused self-management programmes improve patient confidence, wellbeing and disease control compared with standard care?

    Recommendation ID CG153/4 Question Self-management:- Do structured psoriasis-focused self-management programmes improve patient...

    Research recommendation
    Published
    9 June 2015

  6. Methotrexate and risk of hepatotoxicity:- What is the impact of methotrexate compared with other approaches to care (for example other systemic non-biological or biological treatments) on risk of significant liver disease in people with psoriasis and do risk factors such as obesity, alcohol use or diabetes alter this risk?

    biological treatments) on risk of significant liver disease in people with psoriasis and do risk factors such as obesity, alcohol use or...

    Research recommendation
    Published
    9 June 2015

  7. Topical therapy:- In people of all ages with psoriasis: 1. How should topical therapies be used to maintain disease control i) safely; ii) effectively and iii) what are the health economic implications? 2. What are the risks of 'real life' long term corticosteroid use, are there particular people at risk and what strategies can be used to modify or avoid risks?

    CG153/5 Question Topical therapy:- In people of all ages with psoriasis: 1. How should topical therapies be used to maintain disease...

    Research recommendation
    Published
    9 June 2015

  8. Alitretinoin for the treatment of severe chronic hand eczema (TA177)

    Evidence-based recommendations on alitretinoin (Toctino) for treating severe chronic hand eczema in adults.

    Technology appraisal guidance
    Published
    26 August 2009
    View recommendations

    Sections for TA177

  9. Technology appraisal committee A members

    Biographies and registered interests for members of the Technology Appraisal Committee A

  10. Technology appraisal committee A members

    Biographies and registered interests for members of the Technology Appraisal Committee A

  11. Psoriasis - briakinumab (suspended) [ID65]

    Discontinued Reference number: GID-TAG412

    Technology appraisal guidance
    Discontinued

  12. Tofacitinib for treating juvenile idiopathic arthritis (TA735)

    Evidence-based recommendations on tofacitinib for treating juvenile idiopathic arthritis.

    Technology appraisal guidance
    Published
    20 October 2021
    View recommendations

    Sections for TA735

  13. Technology appraisal committee D members

    Find out more about NICE technology appraisals advisory committee D members

  14. Technology appraisal committee D members

    Find out more about NICE technology appraisals advisory committee D members

  15. Remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn's disease and ulcerative colitis (ES35)

    Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn’s disease and ulcerative colitis

    Evidence summary
    Published
    24 February 2021